Fruquintinib for Advanced Colorectal Cancer in Poland
Part of Cancer, Digestive system clinical trials.
This study follows adults in Poland who are receiving fruquintinib, a targeted cancer medicine, for advanced colorectal cancer that has spread. You would be enrolled if your doctor is already planning to give you fruquintinib as a later-line treatment after other therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have metastatic colorectal cancer (cancer that has spread beyond the colon)
- Your doctor plans to treat you with fruquintinib as your third or later line of treatment
- You have already received and either stopped responding to or couldn't tolerate trifluride/tipiracil (a previous cancer drug)
- You are eligible for fruquintinib under Poland's national drug program B.4
- You can provide medical records to support the study's data collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.
This trial tests a combination of two drugs, fruquintinib and tislelizumab, for people with a specific type of advanced colorectal cancer that has not spread to the liver. It is for those whose cancer is stable in certain DNA repair systems (MSS/pMMR) and who have already tried other treatments.
This trial tests a drug called fruquintinib for people with advanced colorectal cancer that has spread. It is for patients who have already tried several standard treatments and need a new option.
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.